Results 1 to 10 of about 3,401,781 (173)
Cytokine Release Syndrome (CRS) and Nicotine in COVID-19 Patients: Trying to Calm the Storm [PDF]
SARS-CoV-2 is a new coronavirus that has caused a worldwide pandemic. It causes severe acute respiratory syndrome (COVID-19), which is fatal in many cases, and is characterized by a cytokine release syndrome (CRS).
Jesus Gonzalez-Rubio +6 more
doaj +10 more sources
Effectiveness of Tocilizumab in a COVID-19 Patient with Cytokine Release Syndrome [PDF]
Cytokine release syndrome (CRS) is a systemic inflammatory response that can be triggered by many factors such as infections. CRS in patients with coronavirus disease 2019 (COVID-19) is life-threatening and can occur very rapidly after COVID-19 diagnosis.
Sadettin Uslu
doaj +2 more sources
In recent decades, many serious respiratory infections have broken out all over the world, including SARS-CoV, MERS, and COVID-19. They are characterized by strong infectivity, rapid disease progression, high mortality, and poor prognosis.
Peixian Chen +6 more
doaj +2 more sources
Cytokine release syndrome caused by immune checkpoint inhibitor: a case report [PDF]
Objective To investigate the diagnosis and treatment of cytokine release syndrome (CRS) caused by immune checkpoint inhibitor(ICI). Methods A case of ICI pembrolizumab leading to CRS was analyzed in Department of Pulmonary and Critical Care Medicine ...
SI Xiao-yan, WANG Han-ping, ZHANG Li, WANG Meng-zhao, ZHANG Xiao-tong
doaj +2 more sources
T cell engaging therapies, like CAR-T cells and T cell engagers, redirect T cells toward tumor cells, facilitating the formation of a cytotoxic synapse and resulting in subsequent tumor cell killing. T cell receptor or CAR-T downstream signaling triggers
Gabrielle Leclercq +5 more
doaj +3 more sources
Interleukin Inhibitors in Cytokine Release Syndrome and Neurotoxicity Secondary to CAR-T Therapy
Introduction: Chimeric antigen receptor T-cell (CAR-T) therapy is an innovative therapeutic option for addressing certain recurrent or refractory hematological malignancies.
Puri Ferreros, Isabel Trapero
doaj +2 more sources
Cytokine release syndrome (CRS) is a major obstacle to the widespread clinical application of chimeric antigen receptor (CAR) T cell therapies. CRS can also be induced by infections (such as SARS-CoV-2), drugs (such as therapeutic antibodies), and some ...
Hanfei Guo, Lei Qian, Jiuwei Cui
doaj +1 more source
Cytokine release syndrome (CRS) is one of the major acute complications caused by massive cytokine release after chimeric antigen receptor (CAR) T-cell therapy. Patients with tumor masses were considered at high risk of local CRS induced by the expansion
Haruko Shima +7 more
doaj +1 more source
Adoptive immunotherapy has recently garnered widespread interests owing to the successful application of chimeric antigen receptor T cell therapy.
Xiaoxue Shi, Hongfang Wu
doaj +1 more source
Chimeric antigen receptor T (CAR-T) cell therapy has achieved remarkable clinical efficacy in treatment of many malignancies especially for B-cell hematologic malignancies. However, the application of CAR-T cells is hampered by potentially adverse events,
Chengxin Luan +10 more
doaj +1 more source

